A Phase 3 interventional study of taldefgrobep alfa and Placebo in Spinal Muscular Atrophy, Neuromuscular Diseases and SMA, sponsored by Biohaven Pharmaceuticals, Inc.. Active, not recruiting at 53 sites in 9 countries. Open to participants aged 4 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Biohaven Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 121 studies in Muscular Atrophy, Spinal with a site in United States — 21 open to participants now, 39 under way, 7 of them phase 3. Muscular Atrophy, Spinal · United States.
Among the 121 studies in Muscular Atrophy, Spinal with a site in United States, this one is the 3rd largest by enrollment of the 76 interventional ones that give a count, is one of 13 that started in 2022, is one of 18 in phase 3, reaches primary completion later than 1 of the 38 other live ones, and was the 86th registered.
282 studies on the registry are indexed under Muscular Atrophy, Spinal; 72 are open to participants now.
Browse Muscular Atrophy, Spinal studies →21 of the 121 studies in Muscular Atrophy, Spinal with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–80
St. Jude Children's Research Hospital · Sites in United States
Biogen · Sites in United States
Ages 0 days–7 mo
Biogen · Sites in United States, China, Japan and 1 more country
Ages 15–60
Novartis Pharmaceuticals · Sites in United States
Ages 2–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 57 Muscular Atrophy, Spinal studies recruiting now, 28 (49%) set no upper age limit and 26 (46%) stop at 75 or younger; 45 take children under 18; 11 take healthy volunteers.
This study: 4 Years to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
121 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 27 · Phase 3 20 · Phase 4 6
First in 1986; this study’s year is marked. 13 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 269 is above the median of 29 across 156 interventional studies indexed under Muscular Atrophy, Spinal.
Median enrollment 33 across the 76 interventional studies, 75 across the 43 observational. Of the 76 that completed or were terminated, 33 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 121 have an industry lead sponsor. The 10 most frequent:
Biohaven Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 7 (64%) have results posted.
Biohaven Pharmaceuticals, Inc. has 1 study filed under Muscular Atrophy, Spinal — fewer than ten, so there is no comparison to draw.
7 of the studies in Muscular Atrophy, Spinal with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05067790Phase 3BiogenA Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND) | 2027-09-24 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT07223320Teachers College, Columbia UniversityHABIT-ILE + FST in Children With SMA | 2026-12-31 |
| NCT07400198Jacqueline MontesGait and Bone Health in SMA | 2027-06-30 |
| NCT06532474St. Jude Children's Research HospitalExploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies | 2027-09 |
Add all 7 to your calendar (.ics) → With an account.
Among the 121 studies in Muscular Atrophy, Spinal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial will study the efficacy and safety of taldefgrobep alfa as an adjunctive therapy for participants who are already taking a stable dose of nusinersen and/or risdiplam and/or have a history of onasemnogene abeparvovec, compared to placebo.
Myostatin is a negative regulator of muscle growth. Blocking myostatin activity has been shown to increase muscle size and function. Taldefgrobep alfa directly blocks myostatin activity and was well tolerated in other clinical studies. In combination with medications that increase the amount of SMN protein in the body, taldefgrobep alfa has the potential to further improve motor function and clinical measures for people living with SMA.
Key Inclusion Criteria:
Key Exclusion Criteria:
taldefgrobep alfa - Double-blind (DB) Phase: Participants receive weight based 35 mg/50 mg weekly subcutaneous injection for 48-week DB phase. taldefgrobep alfa/taldefgrobep alfa - Extension Phase: Participants receive weight based 35 mg/50 mg weekly subcutaneous injection for Open label Extension (OLE) phase.
Drug: taldefgrobep alfa
Placebo - Double-blind (DB) Phase: Participants receive weight based 35 mg/50 mg weekly subcutaneous injection for 48-week DB phase. Placebo/taldefgrobep alfa - Extension Phase: Participants who receive placebo during DB phase, receive weight based 35 mg/50 mg weekly subcutaneous taldefgrobep alfa injection for OLE phase.
Drug: Placebo · Drug: taldefgrobep alfa
DB Phase: 35 mg/50 mg weekly subcutaneous injection
Also known as: BHV-2000, BMS-986089
DB Phase: matching placebo 35 mg/50 mg weekly subcutaneous injection
Extension Phase: 35 mg/50 mg weekly subcutaneous injection
Also known as: BHV-2000, BMS-986089
Efficacy of taldefgrobep alfa compared to placebo in change in the 32 item Motor Function Measure (MFM-32) total score
Change in MFM-32 total score from baseline to Week 48. Scores range from 0-3 on each item. The scores from the 32 items are summed and transformed to a 0-100 scale, with higher scores reflecting higher levels of functional abilities.
Time frame: Baseline to Week 48
Efficacy of taldefgrobep alfa compared to placebo in change in the Revised Upper Limb Module (RULM) score
The RULM includes 20 items, graded from 0 to 2, with a maximum score of 37. Higher scores indicate better function.
Time frame: Baseline to Week 48
Efficacy of taldefgrobep alfa compared to placebo in change in the Revised Hammersmith Scale (RHS)
The RHS has a maximum score of 69 points (33 items are scored 0-2, and 3 items scored 0-1). Higher scores indicate better function.
Time frame: Baseline to Week 48
Change from Baseline in lean body mass
Body mass will be measured as change in kg (greater change meaning more improvement)
Time frame: Baseline, Week 48
Change from Baseline in bone mineral density
Bone mineral density will be measured by Z-score change (higher score indicates improvement)
Time frame: Baseline, Week 48
Change from baseline in Tanner staging
Time frame: Baseline, Week 48
Injection acceptability assessments
If local injection site reactions (such as redness, itching, swelling, hardening or bruising) are experienced, the acceptability is scored on a scale of 1-5 with 1 being totally acceptable and 5 being not at all acceptable If pain is experienced at the injection site, pain will be scored on a scale of 1-5 with 1 being totally acceptable and 5 being not at all acceptable
Time frame: Week 48
Number of Participants with new or worsening lab abnormalities, Adverse Events (AEs), Serious AEs (SAEs) and AEs Leading to Study Drug Discontinuation in the Double-blind Phase
Time frame: Up to 48 Weeks
Trough plasma concentration
Time frame: Baseline, Week 12, Week 24, Week 36, Week 48
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2022 to primary completion in Sep 2024, 26 months.
Of 18 phase 3 interventional studies under Muscular Atrophy, Spinal, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's 26 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Taldefgrobep alfa
Biohaven Pharmaceuticals, Inc.